Episode Details

Summary

In this conversation, Sapna Patel and James Larkin discuss the Checkmate 238 landmark study on adjuvant therapy for melanoma. They touch on various topics, including food choices, pets, and the study design. They highlight the importance of considering the heterogeneity and tempo of melanoma in treatment decisions. They also discuss the challenges of conducting dedicated trials for mucosal and acral melanoma subtypes. Overall, the Checkmate 238 study established the use of adjuvant anti-PD-1 therapy and has long-term follow-up data.

Keywords

melanoma, adjuvant therapy, Checkmate 238, study design, heterogeneity, tempo, mucosal melanoma, acral melanoma

Takeaways

• Consider the heterogeneity and tempo of melanoma when making treatment decisions.
• Dedicated trials are needed to determine the efficacy of adjuvant therapy for mucosal and acral melanoma subtypes.
• The Checkmate 238 study established the use of adjuvant anti-PD-1 therapy for melanoma.
• Long-term follow-up data is important for assessing the efficacy and safety of adjuvant therapy.

Sound Bites

"Unconditionally loyal. Yeah, if only men were like this, right? Yeah, just kidding."

"If you compare the EORTC study with the Checkmate238 study, does NIVO have an OS benefit?"

"Patient selection for treatment is really, really important."

Chapters

00:00 Introduction and Quick Fires

03:12 The Checkmate 238 Landmark Study

08:17 Patient Selection and Challenges in Mucosal and Acral Melanoma

13:05 The Importance of Tempo and Risk of Relapse

16:17 The Need for Dedicated Trials in Mucosal and Acral Melanoma